Search
Erythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalEpoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.
Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5MLMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until … [A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency.
Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidPidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729]. … exercising caution in their recommendation as much more research is necessary [A32981, A32982].
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
Dimethicone 410
go.drugbank.com/drugs/DB14005Approved[L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%. … Dimethicone is a silicone-based polymer used as a moisturizer in different skin OTC products.[A32462] It is formed by repeated polymeric units of -(CH3)2SiO- with a terminal trimethyl siloxy unit.
Desflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalIt was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedFibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. … [A244920] Palovarotene was approved for use in Canada in January 2022 for the management of heterotopic ossification (HO) in patients with FOP, representing the first global approval for any FOP therapy
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.
Tyloxapol
go.drugbank.com/drugs/DB06439ApprovedInvestigationalTyloxapol is a non-ionic detergent often used as a surfactant.
Categories: Compounds used in a research, industrial, or household settingSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalan IgG2 framework. … [eculizumab] in June 2019 and [inebilizumab] in June 2020).
Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringe